Thursday, February 20, 2020 1:09:58 AM
So... no "Made in the USA" sticker is coming to INSULTEX any time soon.
Greendolphin has claimed that IVDN owns patents "worth millions." However, it's unclear to me from the company's filings what patents are actually owned by IVDN. IVDN claims to have filed patent application 12 642714, which was denied by the PTO, but IVDN appealed. It appears to me that the 2018 10K says this appeal is still pending, but the document at https://casetext.com/admin-law/ex-parte-riccelli-et-al-2 suggests to me this appeal has already been denied. So I honestly don't know what's going on there.
I count 3 additional patents that IVDN claims to own in the 10K, but there are no details about any of them, only that they were filed in Dec. 2008, Feb. 2010, and May 2016. "Filing" a patent does not mean that the patent has been granted. I suspect, therefore, that IVDN actually does not own any valid patents at all. (Actually, I take that back; the Feb. 2010 patent "has been allowed." I still don't know what the patent actually is, though, and the USPTO's search site appears to be down.)
The only 'real' asset that IVDN appears to have is an exclusive licensing agreement. They are allowed to sell INSULTEX anywhere in the world except Korea and Japan. However, since they can't manufacture the product themselves, what IVDN really has is the right to buy a product from a manufacturer in Indonesia and sell that product to customers in markets other than Korea and Japan.
However, the manufacturer is under no obligation to actually produce any product that IVDN wishes to order. And if they do decide to satisfy an order from IVDN, there are no agreements on the price that the manufacturer can charge IVDN.
So, IVDN is incapable of manufacturing INSULTEX themselves, and the one (apparently) manufacturer that is (currently) able to make the product is under no obligation to actually produce product that IVDN orders. Which means that even if IVDN *is* able to generate sales, they have no way to ensure that they can deliver the product they just sold.
If it costs too much for IVDN to operate the machine they've already bought to make INSULTEX, I'm very skeptical that they'll be able to find another manufacturer willing to spin up production capability. (Presumably, that would be more expensive than getting the already-existing machine working, which IVDN claims is not economically viable.) So IVDN is entirely at the mercy of the only manufacturer of the product. (This risk is called out in the 10K; I'm just making it obvious.)
I think IVDN is in a world of hurt, and the more I look at this company and the comments others are making, the more I am convinced that the only way for IVDN to succeed is to sell its way out of its current position. Given the company's historical revenues and expenses, I'm not convinced that current management is capable of doing that. Uber, Virgin Galactic, and Tesla all have investors willing to keep pouring money into the companies to keep them afloat. These companies have CEO's that investors have confidence in, and they have plans to get to profitability. IVDN has none of that. (I also don't expect Uber to be around 3 years from now. Tesla I expect will be; they've got some serious competitive advantages and are starting to show profitability. I know nothing about Virgin Galactic but I don't think a comparison between them and IVDN is likely to be relevant.)
Without sales, personal loans from the CEO are only going to be able to keep IVDN running until his pockets are empty. At that point, I don't see a survival strategy for the company.
They'd better get to selling INSULTEX, and selling a lot of it.
Recent IVDN News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/23/2024 07:23:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 07:15:29 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 01/26/2024 05:09:52 PM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 09/27/2023 02:16:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/25/2023 04:53:15 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 09/06/2023 08:05:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/07/2023 04:52:57 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM